Global Investment Priorities in the Communication and Collaboration Space, According to Frost & Sullivan
SANTA CLARA, Calif., March 25, 2021 /PRNewswire/ — Frost & Sullivan’s recent analysis, Communications and…
SANTA CLARA, Calif., March 25, 2021 /PRNewswire/ — Frost & Sullivan’s recent analysis, Communications and…
CONVENING OF THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS OF 30 APRIL 2021 The shareholders are invited…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL…
Topline data expected in the first half of 2021 UNIONDALE, N.Y., March 25, 2021 (GLOBE…
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics B.V. (Nasdaq:…
Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line Lynparza®…
LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) – Seraph Research Institute (SRI)…
NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or…
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association…
2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally…
BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or…
VANCOUVER, British Columbia, March 24, 2021 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“AgraFlora” or…
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of…
Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time YAVNE, Israel, March…
Cash runway into the second half of 2023 Announced positive interim data from EQUATE study…
– Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 – – NASH histology…
MALVERN, Pa., March 24, 2021 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical…
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful…